| Revenue growth | 7% YoY for FY26; Q4 accelerated to 10%. |
|---|---|
| Margins | FY26 EBITDA margin at 21.2%; targeting steady annual expansion. |
| Demand visibility | Strong momentum in Top 10 brands contributing 58% of revenue. |
| Management confidence | High; citing sharper strategic execution and outperforming market growth. |
Growth
FY26 Revenue grew 6.9% to ₹2,872 Mn; Operational PAT rose 19% YoY to ₹446 Mn.
Outlook
Targeting 1.5x IPM growth and 100-150 bps annual margin improvement beyond FY27.
Risks
Regulatory changes, currency fluctuations, and competitive pressures in core therapy segments.
Earnings Call filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹236.58
- Market cap
- ₹1,560 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 34.3×Sector 47.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Business Update
Jagsonpal Pharmaceuticals Ltd has filed its Business Responsibility and Sustainability Report for the financial year 2025-26. This report forms part of its annual report.
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals Ltd has issued the notice for its 47th Annual General Meeting, scheduled for September 18, 2026, alongside the Annual Report for FY 2025-26.
Jagsonpal Pharmaceuticals Other Announcement
The company informed shareholders without registered email addresses of the web-link to access the 2025-26 Annual Report and AGM Notice, per Regulation 36(1)(b).
Jagsonpal Pharmaceuticals Employee Stock Options
Jagsonpal Pharmaceuticals Limited allotted 27,950 equity shares following the exercise of employee stock options. This increases the company's total paid-up share capital to Rs. 13.19 Crore.